<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04514653</url>
  </required_header>
  <id_info>
    <org_study_id>RGX-314-2102</org_study_id>
    <nct_id>NCT04514653</nct_id>
  </id_info>
  <brief_title>RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)</brief_title>
  <acronym>AAVIATE</acronym>
  <official_title>A Phase 2, Randomized, Dose-escalation, Ranibizumab-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered Via One or Two Suprachoroidal Space (SCS) Injections in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regenxbio Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regenxbio Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RGX-314 is being developed as a novel one-time gene therapy treatment for the treatment of&#xD;
      neovascular (wet) age related macular degeneration (wet AMD). Wet AMD is characterized by&#xD;
      loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a&#xD;
      significant cause of vision loss in the United States, Europe and Japan, with up to 2 million&#xD;
      people living with wet AMD in these geographies alone. Current anti-VEGF therapies have&#xD;
      significantly changed the landscape for treatment of wet AMD, becoming the standard of care&#xD;
      due to their ability to prevent progression of vision loss in the majority of patients. These&#xD;
      therapies, however, require life-long intraocular injections, typically repeated every four&#xD;
      to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients&#xD;
      often experience a decline in vision with reduced frequency of treatment over time. RGX-314&#xD;
      is being developed as a potential one-time treatment for wet AMD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase 2, randomized, dose-escalation study is designed to evaluate the efficacy, safety&#xD;
      and tolerability of RGX-314 gene therapy in subjects with nAMD. Approximately 95 participants&#xD;
      who meet the inclusion/exclusion criteria, will be enrolled into one of 5 cohorts.&#xD;
      Participants will be randomized in Cohorts 1 and 2 to receive RGX-314 or Ranibizumab control,&#xD;
      and participants enrolled in Cohorts 3 through 5 will receive RGX-314. Cohort 1 will evaluate&#xD;
      RGX-314 Dose 1, Cohorts 2 and 3 will evaluate RGX-314 Dose 2, and Cohorts 4 and 5 will&#xD;
      evaluate RGX-314 Dose 3. Efficacy will be the primary focus of the study. Participants will&#xD;
      be evaluated for safety and tolerability of RGX-314 throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2020</start_date>
  <completion_date type="Anticipated">January 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the mean change in Best Corrected Visual Acuity (BCVA) for RGX-314 compared with ranibizumab monthly.</measure>
    <time_frame>40 weeks</time_frame>
    <description>The scale used is the early treatment diabetic retinopathy study (ETDRS) letter score from 0-100 and higher score being better vision.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidences of overall and ocular AEs and SAEs</measure>
    <time_frame>52 weeks</time_frame>
    <description>Evaluate the safety and tolerability of RGX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of RGX-314 on choroidal neovascularization (CNV) lesion growth and leakage</measure>
    <time_frame>52 weeks</time_frame>
    <description>Mean change from baseline in CNV lesion size and leakage area based on FA at Week 40 and Week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of RGX-314 on Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Mean change from baseline in Best Corrected Visual Acuity (BCVA) to Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of RGX-314 on central retinal thickness (CRT)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Mean change from baseline in CRT as measured by SD-OCT to Week 40 and Week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the need for supplemental anti-vascular endothelial growth factor (VEGF) therapy in participants who receive RGX-314 treatment</measure>
    <time_frame>52 weeks</time_frame>
    <description>Mean supplemental anti-VEGF injection annualized rate in the RGX-314 treatment arm through Week 40 and Week 52</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Neovascular Age-Related Macular Degeneration (nAMD)</condition>
  <arm_group>
    <arm_group_label>Ranibizumab control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control treatment arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGX-314 Treatment Arm (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGX-314 Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGX-314 Treatment Arm (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGX-314 Dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RGX-314 Treatment Arm (Dose 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RGX-314 Dose 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RGX-314 Dose 1</intervention_name>
    <description>AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)</description>
    <arm_group_label>RGX-314 Treatment Arm (Dose 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RGX-314 Dose 2</intervention_name>
    <description>AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)</description>
    <arm_group_label>RGX-314 Treatment Arm (Dose 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ranibizumab (LUCENTISÂ®)</intervention_name>
    <description>Ranibizumab (anti-VEGF agent)</description>
    <arm_group_label>Ranibizumab control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RGX-314 Dose 3</intervention_name>
    <description>AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)</description>
    <arm_group_label>RGX-314 Treatment Arm (Dose 3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;/= 50 and &lt;/= 89&#xD;
&#xD;
          -  Diagnosis of CNV secondary to age-related macular degeneration in the study eye.&#xD;
&#xD;
          -  Participants must have demonstrated a meaningful response to anti-VEGF therapy.&#xD;
&#xD;
          -  Willing and able to provide written, signed informed consent for this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CNV or macular edema in the study eye secondary to any causes other than AMD.&#xD;
&#xD;
          -  Subfoveal fibrosis or atrophy in study eye.&#xD;
&#xD;
          -  Participants who have had a prior vitrectomy.&#xD;
&#xD;
          -  Any condition in the investigator's opinion that could limit VA improvement in the&#xD;
             study eye.&#xD;
&#xD;
          -  Active or history of retinal detachment in the study eye.&#xD;
&#xD;
          -  Uncontrolled glaucoma in the study eye.&#xD;
&#xD;
          -  Received any gene therapy.&#xD;
&#xD;
          -  Any condition preventing visualization of the fundus or VA improvement in the study&#xD;
             eye, eg, cataract, vitreous opacity, fibrosis, atrophy, or retinal epithelial tear in&#xD;
             the center of the fovea.&#xD;
&#xD;
          -  History of intraocular surgery in the study eye.&#xD;
&#xD;
          -  Receipt of any investigational product within 30 days of Visit 2.&#xD;
&#xD;
          -  Myocardial infarction, cerebrovascular accident, or transient ischemic attacks within&#xD;
             6 months of study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>1-866-860-0117</phone>
    <email>patientadvocacy@regenxbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Phoenix Location</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bakersfield Location</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beverly Hills Location</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mountain View Location</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Poway Location</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Location</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta Location</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baltimore Location</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Location</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reno Location</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albuquerque Location</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philadelphia Location</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Germantown Location</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nashville Location</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Woodlands Location</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 4, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>wet AMD</keyword>
  <keyword>wAMD</keyword>
  <keyword>nAMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Effusions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

